-- XYNTHA contains trace amounts of hamster proteins. Patients treated
with this product could develop hypersensitivity to these nonhuman
mammalian proteins.
-- When clinically indicated, patients should have plasma factor VIII
activity levels monitored by the one-stage clotting assay to confirm
that adequate factor VIII levels have been achieved and are maintained.
-- The most frequently reported adverse reactions in clinical studies were
headache and fever.
Please see XYNTHA full Prescribing Information available at http://www.wyeth.com.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are
forward-looking statements based on current expectations of future events
and are subject to risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such statements.
These risks and uncertainties include the inherent uncertainty of the
timing and success of, and expense associated with, research, development,
regulatory approval and commercialization of our products, including with
respect to our pipeline products; govern
'/>"/>
| SOURCE Wyeth Pharmaceuticals Copyright©2008 PR Newswire. All rights reserved |